Frequency of genetic alterations differs in advanced breast cancer between metastatic sites
Genes, Chromosomes and Cancer · 2024-01 · 63 (1)
DOI: 10.1002/gcc.23199 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, Chromosomes and Cancer, online erschienen am 06.09.2023. Verfasst von Isabel Grote und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pathology, Hannover Medical School, Hannover, Germany. Hauptthemen laut MEDLINE: Breast Neoplasms, Bone Neoplasms, Brain Neoplasms. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Krebshilfe.
Abstract (Originalsprache)
About 20%–30% of breast cancer (BC) patients will develop distant metastases, preferentially in bones, liver, lung, and brain. BCs with different intrinsic subtypes prefer different sites for metastasis. These subtypes vary in the abundance of genetic alterations which may influence the localization of metastases. Currently, information about the relation between metastatic site and mutational profile of BC is limited. In this study, n = 521 BC metastases of the most frequently affected sites (bone, brain, liver, and lung) were investigated for the frequency of AKT1, ERBB2, ESR1, PIK3CA , and TP53 mutations via NGS and pyrosequencing. Somatic mutations were present in 64% cases. PIK3CA and TP53 were the most frequently mutated genes under study. We provide an analysis of the mutational profile of BCs and the affected metastatic site. Genetic alterations differed significantly depending on the organ site affected by metastases. TP53 mutations were mostly observed in brain metastases (51.0%), metastases outside of the brain revealed a much lower proportion of TP53 mutated samples. PIK3CA mutations are frequent in liver (40.6%), lung (36.8%), and bone metastases (35.7%), whereas less common in brain metastases (18.4%). The highest percentage of ESR1 mutations was observed in liver and lung metastases (about 30% each), whereas metastatic lesions in the brain showed significantly less ESR1 mutations, only in 2.0% of the cases. In summary, we found significant differences of mutational status in mBC depending on the affected organ and intrinsic subtype. Organotropism of metastatic cancer spread may be influenced by the mutational profile of individual BCs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Pathology, Hannover Medical School, Hannover, Germany.
ORCID-Profile: Isabel Grote, Matthias Christgen, Stephan Bartels
Förderung
- Deutsche Krebshilfe
Zitieren
APA
Grote, I., Poppe, A., Lehmann, U., Christgen, M., Kreipe, H., & Bartels, S. (2024). Frequency of genetic alterations differs in advanced breast cancer between metastatic sites. Genes, Chromosomes and Cancer, 63(1). https://doi.org/10.1002/gcc.23199
Vancouver
Grote I, Poppe A, Lehmann U, Christgen M, Kreipe H, Bartels S. Frequency of genetic alterations differs in advanced breast cancer between metastatic sites. Genes, Chromosomes and Cancer. 2024;63(1). doi:10.1002/gcc.23199
BibTeX
@article{Grote2024,
author = {Grote, Isabel and Poppe, Alexandra and Lehmann, Ulrich and Christgen, Matthias and Kreipe, Hans and Bartels, Stephan},
title = {Frequency of genetic alterations differs in advanced breast cancer between metastatic sites},
journal = {Genes, Chromosomes and Cancer},
year = {2024},
volume = {63},
number = {1},
doi = {10.1002/gcc.23199}
}
EUVIMED